Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro

OBJECTIVE: Dendritic cells (DCs) are administered as immunotherapeutic adjuvants after the completion of standard treatment in most settings. However, our Phase I trial indicated that one patient out of four, who received autologous tumor lysate-pulsed dendritic cell (TLDC) also received cisplatin c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhandapani, Hemavathi, Seetharaman, Abirami, Jayakumar, Hascitha, Ganeshrajah, Selvaluxmy, Singh, Shirley Sunder, Thangarajan, Rajkumar, Ramanathan, Priya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192235/
https://www.ncbi.nlm.nih.gov/pubmed/33908712
http://dx.doi.org/10.3802/jgo.2021.32.e59

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192235/
https://www.ncbi.nlm.nih.gov/pubmed/33908712
http://dx.doi.org/10.3802/jgo.2021.32.e59

Ejemplares similares